TYMS and non-small cell lung carcinoma: A meta-analysis demonstrated that as a pyrimidine metabolic rate-limiting enzyme (56), TYMS expression was negatively correlated with response rate, overall survival, and progression-free survival in NSCLC patients treated with pemetrexed-based chemotherapy (57).